The antipsychotic drug zotepine [ZTP;f]thiepin-10-yl)oxy]-N,N-dimethylethan-1-amine] is known to have not only atypical antipsychotic effects but also antidepressive effects in schizophrenia patients. Norzotepine [norZTP;f]thiepin-10-yl)oxy]-N-methylethan-1-amine] has been postulated to be a major metabolite of ZTP in humans. Here, we characterized norZTP through several in vitro studies and in animal models of psychosis, depression, and extrapyramidal symptoms (EPS) and compared the pharmacological profiles with those of ZTP. Although both compounds showed similar overall neurotransmitter receptor binding profiles, norZTP showed 7-to 16-fold more potent norepinephrine reuptake inhibition than ZTP. In a pharmacokinetic study, both ZTP and norZTP showed good brain permeability when administered individually in mice, although norZTP was not detected in either plasma or brain after intraperitoneal injection of ZTP. In the methamphetamineinduced hyperlocomotion test in mice, norZTP and ZTP showed similar antipsychotic-like effects at doses above 1 mg/kg i.p. In contrast, unlike ZTP, norZTP did not induce catalepsy up to 10 mg/kg i.p. norZTP significantly antagonized the hypothermia induced by reserpine [(3␤,16␤,17␣,18␤,20␣)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester], suggesting in vivo inhibition of the norepinephrine transporter. In the forced-swim test, norZTP exerted an antidepressant-like effect at the effective doses for its antipsychotic action, whereas ZTP neither antagonized reserpine-induced hypothermia nor showed antidepressant-like effect. These results collectively demonstrate that norZTP exerts more potent inhibitory action than ZTP on norepinephrine transporters both in vitro and in vivo, presumably accounting for its antidepressant-like effect and low EPS propensity. Given that norZTP is the major metabolite observed in humans, norZTP may contribute to the unique clinical profiles of its mother compound, ZTP.
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Zotepine [ZTP; f] thiepin-10-yl)oxy]-N,N-dimethylethan-1-amine; brand name: Lodopin, Zoleptil, or Nipolept] is an antipsychotic drug with low extrapyramidal symptom (EPS) liability (Petit et al., 1996; Cooper et al., 2000; Davis et al., 2003) . Since ZTP was originally developed and launched in Japan in 1982, it has been available as a pharmacotherapeutic agent in treating schizophrenia patients in Germany, the United Kingdom, and 10 other countries in Europe and Asia. Although the term "atypical antipsychotics" did not exist at its development, ZTP was later proposed to be classified as such (Meltzer et al., 1989b; Stockmeier et al., 1993) , along with other drugs exerting antipsychotic activity with low EPS liability, such as clozapine [8-chloro-11 -(4-methylpiperazin-1-yl)-5H-dibenzo [b,e] [1,4]diazepine] (Meltzer et al., 1989a) . Indeed, ZTP is a dopamine D 2 receptor antagonist and serotonin 5-HT 2A receptor antagonist like olanzapine [2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno [2,3-b] [1, 5] benzodiazepine] and risperidone [3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one] (Schotte et al., 1996; Prakash and Lamb, 1998) .
In clinical settings, ZTP has been reported to show not only antipsychotic but also antidepressive and anxiolytic effects in schizophrenia patients (Fleischhacker et al., 1989; Kondo et al., 1993) . Furthermore, ZTP is also known to exert a rapid antimanic effect without inducing depression in severe mania patients (Amann et al., 2005) . In addition to its antagonistic activity on D 2 and 5-HT 2 receptors, ZTP displays bind-ing affinity for the norepinephrine transporter (NET) with potency comparable with that of conventional antidepressants (Leysen et al., 1993; Prakash and Lamb, 1998; Tatsumi et al., 1999) . Shiraga et al. (1999) reported that incubation of ZTP with human liver microsomes produced four metabolites: Ndesmethylzotepine, 3-hydroxyzotepine, zotepine S-oxide, and 2-hydroxyzotepine. A fifth metabolite, zotepine N-oxide, was also detected, but could not be quantified. N-desmethylzotepine and zotepine S-oxide are formed via metabolism by CYP3A4, whereas 3-hydroxyzotepine and 2-hydroxyzotepine are formed via metabolism by CYP2D6 and CYP1A2, respectively (Shiraga et al., 1999) . Among these metabolites, the N-desmethyl metabolite of zotepine [norzotepine, norZTP; f] thiepin-10-yl)oxy]-N-methylethan-1-amine] is known to be a main metabolite of zotepine in humans (the chemical structures are shown in Fig. 1 ). Some reports have been published regarding plasma concentration of norZTP in humans. In one study conducted with 12 young healthy subjects, plasma concentration of norZTP was measured, and C max value of norZTP was approximately 30% of the parent compound in plasma (ZTP at 12.7 ng/ml versus norZTP at 3.79 ng/ml) after administration of 50 mg of ZTP (Velagapudi et al., 1997) . Similar results were observed in a schizophrenia patient (Chou et al., 2005) . These results suggest that norZTP may contribute considerably to the clinical therapeutic effects of its mother compound ZTP, provided norZTP is pharmacologically active.
Pharmacological properties of metabolites of ZTP have not been fully elucidated, and there have been few pharmacological investigations on the profile of norZTP published to date. Albeit only in conference abstracts, it was shown that norZTP and 3-hydroxyzotepine have potent affinity to 5-HT 2A receptors although other metabolites did not show such affinities (Ohki et al., 1999) , and norZTP has affinities to D 1 , D 2 , D 3 , D 4 , and D 5 receptors (Heal and Needham, 1996) .
Here, to characterize the pharmacological action of norZTP and compare its profile with that of ZTP, we evaluated norZTP via in vitro studies and in vivo animal models of psychosis (methamphetamine-induced hyperlocomotion), depression (forced-swim test), and EPS (catalepsy). Furthermore, norZTP was tested by using the apomorphine hydrochloride [APO; 6, 6a, g] quinoline-10,11-diol hydrochloride hydrate (2:2:1)]-induced climbing test to assess in vivo D 2 antagonist activity and using reserpine [(3␤,16␤,17␣,18␤,20␣)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl) oxy]yohimban-16-carboxylic acid methyl ester]-induced hypothermia to assess in vivo NET inhibitory activity.
Materials and Methods
Drugs and Drug Treatment. norZTP was synthesized at Astellas Pharma Inc. (Tsukuba, Japan), and ZTP was obtained from Astellas Tokai Inc. (Shizuoka, Japan). Olanzapine (brand name: Ziprexa) was purchased from Eli Lilly & Co. (Indianapolis, IN) . Drug doses were corrected for salt content (except for desipramine hydrochloride, paroxetine hydrochloride, MAP, and APO). For in vivo tests, MAP was dissolved in saline and injected subcutaneously. APO was dissolved with 0.1% sodium disulfite in distilled water and injected subcutaneously. Reserpine ampoules were opened just before use and also injected subcutaneously. ZTP, norZTP, and olanzapine were dissolved with a drop of hydrochloric acid and diluted with distilled water, and risperidone was dissolved with a drop of 1% tartaric acid and diluted with distilled water. Amisulpride was dissolved with 0.3% lactic acid, and desipramine hydrochloride was dissolved with distilled water. ZTP, norZTP, olanzapine, risperidone, amisulpride, and desipramine were administered by intraperitoneal injection. Paroxetine hydrochloride was dissolved with 0.5% methylcellulose in distilled water and administered orally. All injection volumes were 10 ml/kg.
Receptor Binding Assays. Initial receptor binding screens were conducted with duplicate samples of 1 M ZTP and norZTP evaluated for binding to neurotransmitter receptors, a transporter, ion channels and enzymes by using radioligand assays (performed at Sekisui Medical Inc., Tokyo, Japan jpet.aspetjournals.org release was measured by calcium flux assay using a fluorescent dye (Fluo-4AM; Dojindo Laboratories, Kumamoto, Japan). All compounds were dissolved by using dimethyl sulfoxide, with a final concentration of 1% dimethyl sulfoxide in the assay buffer.
Animals. For pharmacokinetic measurements and the forcedswim test, adult male DBA/2N mice were purchased from Charles River Japan (Yokohama, Japan) and used at 13 to 14 weeks of age. For other behavioral experiments, male ICR mice were purchased from Japan SLC, Inc. (Shizuoka, Japan) and used at 4 to 8 weeks of age. Mice were maintained 10 per cage in plastic cages with ALPHAdri chip bedding (LSG Corporation, Tokyo, Japan). Mice were housed in a temperature-and humidity-controlled colony room (23 Ϯ 3°C and 55 Ϯ 15%, respectively) under a 12-h light/dark cycle with water and laboratory chow supplied ad libitum. All in vivo experimental procedures were performed during the light cycle. Procedures involving animals and their care were conducted in accordance with the institutional guidelines that are in compliance with international laws and policies (International Guiding Principles for Biomedical Research Involving Animals developed by the Council for International Organization of Medical Science). All experiments were also conducted in accordance with the Astellas Pharma Inc. guidelines for the care and use of animals and under approved protocols from the Institutional Animal Care and Use Committee of Astellas Pharma Inc.
Pharmacokinetic Study in Mice. For pharmacokinetic analysis, 3.2 mg/kg ZTP or norZTP was administered intraperitoneally to 14-week-old male DBA/2N mice, and plasma and brain samples were collected at 0.5, 1, 2, and 4 h after drug administration and stored at Ϫ20°C until use. ZTP and norZTP in plasma and brain were quantified by using high-performance liquid chromatography (HPLC)/ tandem mass spectrometry assay. In brief, plasma samples (50 l) were treated by protein precipitation with the addition of acetonitrile (200 l) containing diazepam [7-chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one] (Wako Pure Chemicals, Tokyo, Japan) as internal standard (final concentration; 20 ng/ml). After centrifugation (1500g, 10 min, 15°C), the supernatant was separated and used for analysis. Brain samples were homogenized with a sodium bicarbonate solution. After addition of internal standard and t-butyl methyl ether, the mixture was shaken for 15 min and centrifuged. The organic layer was then separated, evaporated to dryness under nitrogen, and reconstituted in mobile phase for assay. ZTP and norZTP extracted from plasma and brain were analyzed with an API 3200TM Triple Quadrupole Mass Spectrometer (Applied Biosystems, Tokyo, Japan) coupled to a Shimadzu HPLC system (Shimadzu Scientific Instruments, Kyoto, Japan). Samples were injected into an HPLC column (XTerra MS C18, 5 m, 4.6 ϫ 50 mm; Waters, Tokyo, Japan) and eluted at 40°C. The mobile phase, pumped at 0.4 ml/min, was a mixture of 20 mM ammonium acetate-acetonitrile [30:70 (v:v) ]. The K p value was the ratio of drug concentration in brain (ng/g brain) to plasma (ng/ml) at 30 min after drug injection.
Apomorphine-Induced Climbing and Gnawing. Male ICR mice (4 weeks old) were individually allowed at least 1 h to acclimate to the wire-mesh cage (length ϫ width ϫ height: 130 ϫ 180 ϫ 250 mm). APO is a D 2 /D 1 receptor agonist that is known to induce stereotyped behaviors such as oral stereotypy (gnawing, licking, and biting) at higher doses than those that induce climbing. APO was used at 2 mg/kg in the present study because this dosage has been shown to be the minimum effective dose that induces stable climbing behavior without consequent oral stereotypy.
Each compound or vehicle was injected 20 min before APO was injected, and 20 min after injection of APO (2 mg/kg s.c.), duration of climbing behavior was measured for 2 min. Holding four paws against the wall was counted as climbing behavior. Gnawing was assessed by scoring, with a score of 0 for 0 to 9 times, 1 for 10 to 19 times, and 2 for more than 20 instances of gnawing in 2 min. As reference drugs, atypical antipsychotics, olanzapine, risperidone, and amisulpride, were also examined.
Methamphetamine-Induced Hyperlocomotion Test. In the MAP-induced hyperlocomotion test, male ICR mice (4 -5 weeks old) were used. Individual mice were placed in experimental cages (length ϫ width ϫ height: 300 ϫ 350 ϫ 175 mm) for an acclimatization period before 60 min of MAP injection. All compounds were administered 30 min before MAP injection, and locomotor activity were measured immediately after injection of saline or MAP (1 mg/kg s.c.). Locomotor activity was measured for 30 min by using SUPERMEX (Muromachi Kikai Co., Ltd., Tokyo, Japan). Data were analyzed by using CompAct AMS version 3.51 (Muromachi Kikai Co., Ltd.). As reference drugs, olanzapine and risperidone were also examined.
Spontaneous Locomotor Test. Male ICR mice (4 -5 weeks old) were injected with drugs or vehicle (intraperitoneally) and returned to their home cage. Thirty minutes later, mice were placed in experimental cages (length ϫ width ϫ height : 300 ϫ 350 ϫ 175 mm), and locomotor activity was recorded for 30 min by using SUPERMEX.
Reserpine-Induced Hypothermia. Male ICR mice (7-8 weeks old) were placed in gray (two sides and top cover) and transparent (two sides) individual plastic cages (length ϫ width ϫ height: 120 ϫ 180 ϫ 170 mm) with ALPHA-dri chip bedding (LSG Corporation). Measurement of body temperature was performed 0, 4, and 7 h after starting the experiment, using an intrarectum probe (Physitemp Instruments Inc., Clifton, NJ). Reserpine (3 mg/kg s.c.) was administered at 0 h (experiment initiation), and mice were subsequently injected with drug 4 h after reserpine treatment. Body temperature change was measured 3 h after drug treatment.
Forced-Swim Test. Antidepressant-like effect was evaluated for norZTP, ZTP, olanzapine, and risperidone in the forced-swim test with the doses used in the MAP-induced hyperlocomotion test. The conventional antidepressants desipramine and paroxetine were examined as reference compounds. DBA/2N male mice (13-14 weeks old) were administered either vehicle or test compounds intraperitoneally 30 min before testing, except for paroxetine that was administered orally 60 min before testing.
The forced-swim test was performed in a pool (cylinder diameter: 140 mm) at a water depth of 130 mm and water temperature of 23 to 24°C. Animals were tested in an automated forced-swim apparatus (MV-20LAN; MELQUEST Ltd., Toyama, Japan). Immobility time was calculated from activity time as (total) Ϫ (active) time by using analysis software of the apparatus. Cumulative immobility time was scored for 6 min during the test.
Catalepsy Test. Male ICR mice (5 weeks old) were used. Catalepsy was measured 30 min after intraperitoneal injection of ZTP, norZTP, antipsychotics, or vehicle. The forepaws of the mice were placed on a horizontal steel bar (diameter 3 mm) elevated 3 cm above the tabletop. If duration of catalepsy reached 30 s, catalepsy was scored as positive. Incidence of catalepsy was expressed as the number of mice scored as positive versus the total number of mice evaluated in a group.
Statistical Analysis. Behavioral data were reported as means Ϯ S.E.M., and all statistical analyses were conducted by using SAS version 8.2 (SAS Institute, Cary, NC). Dunnett's multiple comparison test was used to evaluate multiple groups including vehicle and test compounds in all tests except for the catalepsy test, in which vehicle-treated and drug-treated groups were compared by using Steel's test. Student's t test for unpaired data was used to compare MAP-or APO-treated group data with control group data. For all tests, a value of p Ͻ 0.05 was considered statistically significant. ED 50 values were calculated by using linear regression.
Results
Receptor Binding Affinities. ZTP and norZTP were subjected to multitarget binding screening against G proteincoupled receptors, ion channels, a neurotransmitter transporters, and enzymes (Table 1) . Both compounds showed Table  1 , including adenosine A 1 , ␤-adrenergic receptor, GABA A and GABA B , and histamine H 2 and H 3 receptors. K i values were determined for compounds exhibiting more than 50% inhibition in the initial test at 1 M.
As shown in Table 2 , ZTP and norZTP demonstrated high affinity (K i Ͻ10 nM) for D 2 , 5-HT 2A , 5-HT 2C , 5-HT 6 , 5-HT 7 , ␣ 1A , and H 1 receptors; moderate affinity (K i ϭ 10 -100 nM) for ␣ 2A and D 1 receptors; and low affinity (K i ϭ 100-1000 nM) for 5-HT 1A and M 1 receptors. Affinity of norZTP for D 2 , M 1 , and H 1 receptors was more than 3-fold less potent than that of ZTP (Table 2) .
Functional Assay for Norepinephrine and Serotonin
Transporter in Vitro. In HEK293 cells transiently expressing mouse NET, ZTP demonstrated norepinephrine reuptake inhibition comparable with the conventional tricyclic antidepressant imipramine (ZTP IC 50 71 Ϯ 23 nM; Table 3 ). Norepinephrine reuptake inhibition by norZTP was also potent (IC 50 11 Ϯ 1.4 nM), more so than ZTP (Table 3 ). The antidepressant desipramine also showed a similar potency to inhibit mouse NET (IC 50 9.4 Ϯ 5.8 nM; Table 3 ). (ϩ)-(S,S)-reboxetine showed potent inhibition for NET (Table 3 ) (IC 50 2.7 Ϯ 1.1 nM), findings that have been previously reported as well (Zeng et al., 2009) . In HEK293 cells transiently expressing human NET, norZTP showed 16-fold more potent inhibi- Test substance concentration was 1 M. Positive substance concentration was 1 M for HOE140, endtoherin-1, leukotriene B 4 , leukotriene D 4 , and VIP; 100 M for Ro 16-6491; or 10 M for the others. Data are expressed as the mean values of duplicate measurements. The inhibition rate was calculated from 100 Ϫ binding ratio, with binding ratio calculated as ͓(B Ϫ N)/(B0 Ϫ N)͔ ϫ 100 (%), where B is total bound radioactivity in the presence of the test substance (individual value), B0 is total bound radioactivity in the absence of the test substance (mean value), and N is nonspecific bound radioactivity (mean value). 
Pharmacology on a Major
Although both ZTP and norZTP showed weak or minimal inhibition of human and mouse SERT (IC 50 Ͼ 5000 nM), this effect was more than 100-fold less potent than their inhibition of NET (Table 3 ). In the present study, paroxetine showed potent inhibition on mouse SERT (IC 50 4.7 Ϯ 0.1 nM). Neither desipramine nor (ϩ)-(S,S)-reboxetine showed inhibitory activity for SERT.
Histamine H 1 Receptor Binding and Functional Assay. Although norZTP demonstrated affinity for the human H 1 receptor (K i 1.6 Ϯ 0.03 nM), ZTP's affinity was three times more potent (K i 0.47 Ϯ 0.02 nM; Table 2), and both compounds showed negligible affinities (less than 50% inhibition at 1 M) for the histamine H 2 and H 3 receptors (Table 1) . In functional assays, both norZTP and ZTP showed antagonistic activity to the H 1 receptor, although ZTP's activity was four times more potent [corrected IC 50 8.0 Ϯ 1.8 nM (ZTP) versus 38 Ϯ 1.1 nM (norZTP); norZTP corrected IC 50 value comparable with risperidone (26 Ϯ 0.9 nM)] (Table 4 ). In the functional assay, olanzapine showed 8-and 38-fold more potent antagonistic activity (1.1 Ϯ 0.3 nM) than did ZTP and nor-ZTP, respectively, whereas neither ziprasidone nor haloperidol showed any significant antagonistic activity (Ͼ300 nM) ( Table 4) .
Pharmacokinetic Study. After administration of ZTP (3.2 mg/kg i.p.) in mice, ZTP was detected in plasma and brain (Fig. 2) ; however, the concentration of norZTP in these tissues was under the detection limit (20 ng/ml). After administration of norZTP in mice (3.2 mg/kg i.p.), norZTP was detected in both plasma and brain (Fig. 2) . Both ZTP and norZTP showed good brain permeability, and their brain-toplasma concentration ratios (K p ) were 22 and 24, respectively, at 30 min after individual injection. Brain C max (mean Ϯ S.E.M.) values were 918 Ϯ 18 ng/g tissue (ZTP) and 639 Ϯ 209 ng/g tissue (norZTP). Brain area under the curve (0 -4 h; mean Ϯ S.E.M.) of ZTP was 2-fold higher than that of norZTP (ZTP: 2645 Ϯ 195 ng⅐h/g; norZTP: 1018 Ϯ 243 ng⅐h/g; n ϭ 3). Based on these pharmacokinetic data, an intraperitonial injection route for norZTP and ZTP for subsequent in vivo studies was selected, because ZTP was not metabolized to norZTP with this route in mice, which would presumably allow us to interpret the in vivo data of norZTP and ZTP as pharmacological actions of each individual compounds unlike in human cases.
Apomorphine-Induced Climbing Test and Gnawing Behavior. On average, APO-injected control mice (2 mg/kg s.c.) climbed for more than 110 s during the 120-s observation period, in contrast to the vehicle-treated mice, which climbed for less than 10 s during observation. As shown in Table 5 , both ZTP (0.3-3 mg/kg i.p.) and norZTP (1-10 mg/kg i.p.) dose-dependently inhibited climbing behavior. In particular, ZTP significantly reduced climbing time at 1 and 3 mg/kg (p Ͻ 0.05 and 0.001, respectively), compared with vehicletreated animals. In contrast, norZTP had no effect on climbing at 1 and 3 mg/kg, and significant reduction was observed only at 10 mg/kg i.p. ZTP showed 5-fold more potent activity than norZTP, with ED 50 values of 0.73 and 3.9 mg/kg, respectively (Table 5 ). Olanzapine and risperidone showed climbing inhibition, and their ED 50 values were comparable with previously reported values (Corbett et al., 1995) . Treatment with norZTP (3 mg/kg i.p.) and amisulpride (10 and 30 mg/kg i.p.) after APO administration (2 mg/kg s.c.) significantly induced gnawing behavior (Table 5) .
Methamphetamine-Induced Hyperlocomotion. Antipsychotic activity of ZTP and norZTP was assessed by using MAP (1 mg/kg s.c.)-induced hyperlocomotion, with olanzapine and risperidone included as reference compounds. All compounds showed dose-dependent inhibition of MAP-induced hyperlocomotion (Table 6) . Specifically, ZTP (1 and 3 mg/kg i.p.) and norZTP (1, 3, and 10 mg/kg i. p.) significantly inhibited MAP-induced hyperlocomotion, with comparable ED 50 values (0.27 and 0.33 mg/kg, respectively) ( Table 6) .
Spontaneous Locomotor Activity. Effects of ZTP, nor-ZTP, and antipsychotics on spontaneous locomotor activity of mice were investigated without MAP administration. Both ZTP and norZTP showed sedative effects at doses exceeding 3 mg/kg i.p., and ED 50 values between the two were comparable (3.3 and 3.1 mg/kg, respectively) ( Table 7) . Other compounds significantly reduced spontaneous locomotor activity All compounds were injected intraperitoneally 20 min before APO treatment (2 mg/kg, s.c.). ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001; statistically significant compared with APO alone-treated control group (0), as assessed with Dunnett's multiple comparison test. ###, P Ͻ 0.001; statistically significant compared with APO alone-treated control group as assessed using Student's t test. Climbing time and gnawing score criteria are described under Materials and Methods, and data are shown as mean Ϯ S.E.M.
TABLE 6
Effects of zotepine, norzotepine, and other reference antipsychotics on MAP-induced hyperlocomotion in mice
In the MAP-induced hyperlocomotion test, mice were placed in experimental cage for an acclimatization period before 60 min of MAP injection. All compounds were administered 30 min before MAP injection, and locomotor activity was measured immediately after injection of saline or MAP (1 mg/kg s.c.). All activity count data are shown as mean Ϯ S.E.M. with n ϭ 7 to 8 mice per treatment. ##, P Ͻ 0.01; ###, P Ͻ 0.001; statistically significant compared with MAP-alone controls, as assessed using Student's t test. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001; statistically significant compared with MAP control, as assessed using Dunnett's multiple comparison test. at relatively high doses, and those ED 50 values were higher than those observed for the MAP-induced hyperlocomotion test (Table 6) . Catalepsy. norZTP did not induce catalepsy in mice when administered at dosages up to 10 mg/kg. In contrast, zotepine (10 mg/kg i.p.), olanzapine (1-3 mg/kg i.p.), and risperidone (0.3 mg/kg i.p.) showed significant catalepsy induction (Table  7) , with catalepsy-inducing ED 50 values comparable with spontaneous activity inhibitory doses.
Reserpine-Induced Hypothermia. The reserpine-induced hypothermia test is commonly used when developing pharmacological profiles for antidepressants in vivo, as norephinephrine reuptake inhibitors reverse the hypothermia induced by reserpine treatment (Wong et al., 2000) . In the present study, desipramine (0.3-3 mg/kg i.p.) showed dosedependent inhibition of reserpine-induced hypothermia (ED 50 0.46 mg/kg) (Fig. 3) , confirming that this compound does indeed have norepinephrine uptake inhibition activity in vivo. norZTP (0.1-1 mg/kg i.p.) also demonstrated dose-dependent inhibition of hypothermia (ED 50 0.23 mg/kg), with a statistically significant change observed at a dosage of 1 mg/kg (p Ͻ 0.001), the same dose level that produced antipsychotic-like effects in the MAP-induced hyperlocomotion test (Fig. 3 and Table 6 ). At 0.3 mg/kg, norZTP showed 58% inhibition, a value not statistically significant, whereas ZTP showed 45% inhibition at 3 mg/kg and 56% inhibition at 10   TABLE 7 Effects of zotepine, norzotepine, and other reference antipsychotics on spontaneous locomotor activity and incidence of catalepsy in mice Each spontaneous activity value represents the average number of instances of spontaneous locomotor activity, measured for 30 min immediately after the animal was placed on experimental cage. All compounds were administered intraperitoneally 30 min before activity count started. Each catalepsy value represents incidence of catalepsy (sustained bar-hold posture exceeding 30 s). All spontaneous activity count data are shown as mean Ϯ S.E.M., with n ϭ 7 to 8 mice per treatment. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001; statistically significant compared with vehicle control, as assessed using Dunnett's multiple comparison test for spontaneous locomotor activity. #, P Ͻ 0.05; ##, P Ͻ 0.01; ###, P Ͻ 0.001; statistically significant compared with vehicle-treated control as assessed using Steel's test for catalepsy. Fig. 3 . Effects of zotepine, norzotepine, and other antipsychotics and antidepressants on reserpine-induced hypothermia in mice. Four hours after reserpine (3 mg/kg s.c.) administration, mice were injected with each drug. Body temperature change was measured 3 h after drug treatment. All data are shown as mean Ϯ S.E.M., and all compounds were tested at n ϭ 8, except paroxetine (n ϭ 5). ‫,ءءء‬ p Ͻ 0.001, statistically significant compared with the control group treated with reserpine alone, as assessed with Dunnett's test.
mg/kg, values that were also not statistically significant. Neither olanzapine, risperidone, nor paroxetine attenuated the hypothermia at any of the dose levels that induced antipsychotic-like effects. Forced-Swim Test. In the forced-swim test, mice became immobile when placed in a water bath. The duration of immobility relative to vehicle-treated mice was significantly reduced with treatment with norZTP at 1 and 3 mg/kg i.p. (p Ͻ 0.05 and Ͻ 0.001, respectively), doses that were comparable with the effective doses observed in MAP-induced hyperlocomotion test (Fig. 4 and Table 6 ). Although ZTP induced a 29% reduction in immobility time at 3 mg/kg, this change was not statistically significant, and the effect was reversed at 10 mg/kg (data not shown). Paroxetine (3, 10, and 30 mg/kg p.o.) and desipramine (10 and 20 mg/kg i.p.) showed dose-dependent reduction in immobility time (Fig. 4) , as reported previously (Lucki et al., 2001; Ghasemi et al., 2009) . Neither olanzapine nor risperidone showed any effects in the forced-swim test at the doses used.
Discussion
Investigations regarding drug metabolites often lead to novel findings providing biological background information for clinical effects or unexpected side effects of mother compounds. For example, active metabolites of clozapine (Burstein et al., 2005) and quetiapine (Jensen et al., 2008; Winter et al., 2008) have been reported to have unique profiles differing from that of their mother compounds. A recent report showed that a metabolite of quetiapine (N-desalkylquetiapine) is capable of inhibiting norepinephrine uptake, suggesting that the antidepressant effect of quetiapine in bipolar depression is at least partially mediated by the potent antidepressant activity of N-desalkylquetiapine (Jensen et al., 2008) . In this regard, clinical reports demonstrating that N-desmethyl zotepine, norZTP, is a main metabolite of zotepine observed after oral administration of ZTP in humans have prompted us to investigate the pharmacological profiles of norZTP.
The initial aim of the present study, therefore, was to compare in vitro pharmacological properties of norZTP with those of ZTP. Thorough in vitro panel screening of ZTP and norZTP with regard to affinity for the number of neurotransmitter receptors showed that both compounds had relatively similarly potent affinities for D 2 , 5-HT 2A , 5-HT 2C , 5-HT 6 , 5-HT 7 , ␣ 1A , H 1 , and D 1 receptors at therapeutically relevant concentrations and had similar affinities to 5-HT 1A , ␣ 2A , and M 1 receptors at high concentrations. These observations suggest that norZTP has an overall binding profile similar to that of ZTP for important neurotransmitter receptors known to be responsible for ZTP's antipsychotic activity.
The major finding of the present in vitro study was that norZTP potently inhibits norepinephrine reuptake. Although ZTP is structurally similar to tricyclic antidepressants and has been reported to show norepinephrine transporter binding affinity (Leysen et al., 1993; Prakash and Lamb, 1998; Tatsumi et al., 1999) , we demonstrated for the first time in the present study the more potent norepinephrine reuptake inhibitory activity of norZTP by using cell-based functional assay, closely comparable with that of conventional antidepressants. These results suggest that NET inhibitory activity of norZTP may contribute to the clinical effects of ZTP, at least in part.
In the present study, both ZTP and norZTP inhibited MAPinduced hyperlocomotion and APO-induced climbing behavior, indicating that norZTP itself exerts antipsychotic-like effects similar to those of ZTP and other antipsychotics. The ratio of norZTP and ZTP ED 50 values for inhibition of APOinduced climbing (3.9 mg/kg versus 0.73 mg/kg) corresponded jpet.aspetjournals.org to their ratio of K i values of D 2 receptor binding (6.5 versus 2.3 nM), suggesting again that norZTP exerts antipsychotic activity similar to ZTP, presumably involving D 2 receptor blockade. However, the ED 50 value of norZTP required for inhibition of MAP-induced hyperlocomotion was actually comparable with that of ZTP. Because MAP increases concentrations of several neurotransmitters in extracellular fluid (Gough et al., 2002) , antagonisms of 5-HT and H 1 receptors and a number of other mechanisms have been suggested to be involved in the inhibitory activities of antipsychotics on such MAP-induced behaviors. As such, the present findings suggestive of norZTP's D 2 -blocking activity do not fully explain the inhibitory activity of norZTP on MAP hyperlocomotion, indicating that other mechanisms may be involved in this activity.
The forced-swim test is standard for assessing antidepressant-like activity (Porsolt et al., 1978) and existing antidepressants (tricyclics, selective norepinephrine and serotonin reuptake inhibitors, and monoamine oxidase inhibitors) are active in this test. In the present study, norZTP demonstrated antidepressant-like effects at doses that also showed antipsychotic-like effects, whereas ZTP showed no significant antidepressant-like effects at comparable doses. Although there is the possibility that ZTP may exhibit antidepressantlike effect at higher doses, these potential effects may not be detected because of ZTP's sedative effect seen at doses exceeding 3 mg/kg, and we actually observed the reversal of the activity toward the baseline at 10 mg/kg (data not shown). Mice with genetically altered serotonin 5-HT 1A , 5-HT 2A , ␣ 2A , and 5-HT 7 receptors exhibited depression or antidepressantrelated phenotype, and agonists or antagonists of these receptors have been reported to induce antidepressant-like effects in the forced-swim test (Cryan et al., 2002) . Jensen et al. (2008) suggested that the antidepressant activity of quetiapine is at least partially mediated by the NET inhibitory activity and partial 5-HT 1A agonistic and 5-HT 7 antagonistic activity of N-desalkylquetiapine. A recent report has indicated that amisulpride has high affinity for the 5-HT 7A receptor and the compound's antidepressant-like effects disappeared in knockout mice lacking the 5-HT 7 receptor, suggesting that 5-HT 7A antagonism is important for amisulpride to exert its antidepressant-like activity (Abbas et al., 2009) . ZTP is known to have high affinity for 5-HT 7 receptor (Roth et al., 1994) , and the present study revealed that not only ZTP but also norZTP shows similar high affinity for 5-HT 7 receptor (K i 4.6 and 3.7 nM, respectively). However, although risperidone was shown to have high affinity for the 5-HT 7 receptor (Roth et al., 1994) , we observed no antidepressant-like effects here. These findings suggest that NET inhibitory activity may play a major role in norZTP's antidepressant-like effect, whereas additional receptors (such as 5-HT 1A , 5-HT 2A , ␣ 2A , and 5-HT 7 ) may also be involved and merit further exploration.
Although NET inhibition by norZTP is assuredly the mechanism most likely involved in the compound's antidepressant effect, this inhibition may also be involved in norZTP's low induction of EPS and weight gain and the potentiation of antipsychotic action of the parent compound. Reboxetine, a norepinephrine reuptake inhibitor (NRI) introduced relatively recently, reportedly enhances the antipsychotic-like activity of the D 2 blocker raclopride in rat conditioned avoidance and potentiates D 2 blocker-induced dopamine release in the medial prefrontal cortex in rats (Linnér et al., 2002) . Furthermore, a clinical report has indicated that reboxetine attenuates appetite and weight gain in olanzapine-treated schizophrenia patients (Poyurovsky et al., 2007) . However, the effects of NET inhibition on antipsychotic-induced catalepsy have not been well investigated and still warrant further investigations. Pretreatment with reboxetine has been reported to have no effect on racropride-induced catalepsy in rats (Linnér et al., 2002) . However, in our preliminary study, (ϩ)-(S,S)-reboxetine, an NRI with greater selectivity for NET than reboxetine (Wong et al., 2000; Zeng et al., 2009 ), significantly attenuated haloperidol-induced catalepsy with concomitant injection (unpublished observation). Taken together, these findings suggest that NET inhibition may contribute to catalepsy attenuation, and the NET inhibitory activity of norZTP may be involved in the unique in vivo profile demonstrated in the present study. Further studies are nevertheless required to clarify the detailed mechanisms behind the reduced propensity of EPS associated with NET inhibition.
norZTP and amisulpride both significantly potentiated APO-induced gnawing at doses similar to those found to inhibit climbing behavior. Similar observations were reported on amitriptyline, imipramine, and clozapine (Hedley and Wallach, 1983) . These results may suggest that direct or indirect dopamine receptor potentiation and blocking were occurring simultaneously. Studies have shown that NET reuptakes not only norephinephrine but also dopamine (Carboni et al., 2006) . In vivo microdialysis study showed that ZTP increases dopamine and norepinephrine release from the rat frontal cortex (Rowley et al., 2000; Nakamura et al., 2005) , and therefore norZTP may increase extracellular dopamine and stimulate dopamine neurons indirectly through NET inhibition. Although further studies are still needed to investigate the possible relationship between NET inhibition and gnawing potentiation, these data may indicate that NRIs indirectly stimulate dopamine receptors and induce potentiation of the striatal function.
In addition to its inhibitory activity on NET, norZTP showed affinity for other receptors differing from that observed with ZTP. In particular, norZTP's affinity for 5-HT 1A , H 1 , and M 1 receptors was less potent than that of ZTP. H 1 receptor affinity has been reported to be positively correlated with the side effect of body weight gain (Kroeze et al., 2003) . Indeed, olanzapine and clozapine, which show high affinity for the H 1 receptor, are the two antipsychotics known to have the greatest propensity to induce weight gain (Nasrallah, 2008) . Although ZTP and norZTP both showed affinity for H 1 receptors in the binding assay, on evaluating the H 1 receptor antagonistic activity of these compounds in functional assay, we observed that ZTP was less potent than olanzapine, whereas norZTP was less potent than even ZTP. Although the ability of ZTP to induce weight gain has not been extensively documented, several clinical reports have shown that ZTP use in schizophrenia patients is associated with weight gain to an extent comparable with other atypical antipsychotics such as risperidone or quetiapine, albeit not as significantly as olanzapine and clozapine (Baptista et al., 2002) . Although norZTP showed weaker affinity to the histamine H 1 receptor than ZTP in the present study, subsequently suggesting lower weight gain-inducing ability than ZTP, further clinical data regarding the relationship between plasma concentrations of ZTP and norZTP and weight gain in patients is required to better understand the contribution of norZTP to this side effect of ZTP.
In conclusion, the present study demonstrated norZTP's potent in vitro and in vivo activity to inhibit NET, a target molecule of existing antidepressants, and additionally showed that norZTP has antidepressant-like activity in preclinical animal models. Taken together, these findings suggest that norZTP may contribute to the unique clinical profiles of its mother compound, ZTP.
